


Supplementary Material

Supplementary table 1: List of Primers Used in the Present Study.


Gene	Primer Sequences	Reference	Genbank no
<i>Abca1</i>	5'GCAGATCAAGCATCCCAACT3' 3'CCAGAGAATGTTTCATTGTCCA5'	(Hirai et al., 2007)	NM_013454.3
<i>Abcb1a</i>	5'GGGCATTACTTCAAACCTGTCA3' 3'TTTACAAGCTTCATTTCTAATTCAA5'	(Hirai et al., 2007)	NM_011076.3
<i>Abcb1b</i>	5'AAGCCAGTATTCTGCCAAGCAT3' 3'CTCCAGACTGCTGTTGTCTGATG5'	(Hirai et al., 2007)	NM_011075.2
<i>Abcb4</i>	5'GAAGGGATCTACTTCAGACTCGTT3' 3'TCAAATCAAATTCTTCTGACAGG5'	(Hirai et al., 2007)	NM_008830.2
<i>Abcc2</i>	5'TAATGAGGCGCCGTGGGTGAC3' 3'GTCCTGCCACACACCGAC5'	(Hirai et al., 2007)	NM_013806.2
<i>Abcc5</i>	5'AAATGTATGCCTGGGTCAAAGC3' 3'TGGCGATCACTACCACAATAGG5'	*	NM_013790.2
<i>Abcf2</i>	5'TGTCCACATTATCAACCTCTCCC 3' 3'TCACGTTTCCCAATAGCCGAG 5'	*	NM_013853.2
<i>Abcg1</i>	5'GCTCCATCGTCTGTACCATCC3' 3'ACGCATTGTCCTTGACTTAGG5'	*	
<i>Abcg2</i>	5'GCCTTGGAGTACTTTGCATCA3' 3'AAATCCGAGGGTTGTTGTA5'	(Merrell et al., 2014)	NM_011920.3
<i>Il6</i>	5'GAGGATACCACTCCCAACAGACC 3' 3'AAGTGCATCATCGTTGTTACATA 5'	(Murakami et al., 2013)	NM_031168.2
<i>Cxcl1</i>	5'ACCCGCTCGCTTCTCTGT 3' 3'AAGGGAGCTTCAGGGTCAAG 5'	(Murakami et al., 2013)	NM_008176.3
<i>Ccl2</i>	5'GGTCCCTGTCATGCTTCTGG 3' 3'CCTGCTGCTGGTGATCCTCT 5'	(Zammit et al., 2013)	NM_011333.3
<i>Pparg</i>	*	*	NM_001127330.2
<i>CD36(FAT)</i>	5'CGCAGCCTCCTTTCCACCTTTTGT3' 3' TGGTTGTCTGGATTCTGGAGGGGT5'	*	NM_001159556.1
<i>Fatp1</i>	5'CGCTTTCTGCGTATCGTCTG3' 3'GATGCACGGGATCGTGTCT5'	*	NM_011977.4
<i>Fabppm</i>	5'GCGTCCCAGAGCAGTGAAGGA3' 3'GGCATACGATTGGCAGAGGCAGA5'	*	NM_010325.2
<i>Lpl</i>	5'TGGCGTAGCAGGAAGTCTGA3' 5'TGCCTCCATTGGGATAAATGTC3'	*	NM_008509.2
<i>B2m</i>	5'TTCTGGTGCTTGTCTCCAGTATGTT3' 5'GCTTCCCATTCCTGA3'	*	NM_011149.2
<i>B-actina (Actb)</i>	5'AAATCTGGCACCACACCTTC3' 5'GGGGTGTTGAAGGTCTCAA3'	(Coughlin et al., 2016)	NM_007393.5
<i>Gapdh</i>	5'TGTGTCCGTCGTGGATCTGA 3' 3'TTGCTGTTGAAGTCGAGGAG 5'	(Gong et al., 2014)	NM_001289726.1
<i>Ywhaz</i>	5' GAAAAGTTCTTGATCCCAATGC 3' 5' TGTGACTGGTCCACAATTCCTT 3'	*	NM_011740.3

*Gene specific primers were designed with primer-BLAST (<http://www.ncbi.nlm.gov/tools/primer-blast>).


A




B




Supplementary figure 1: Study Design.




Supplementary figure 2: Representative image of TLC plate from maternal plasma at GD 15.5 and 18.5. 15.5/4h: n=6 (control group); n=5 (LPS group). CE: Cholesterol Ester; TG: Triacylglycerol; FFA: Free Fatty Acids; CHO: Free Cholesterol; MG: Monoacylglycerol; PL: Phospholipids.




Supplementary figure 3: Representative image of TLC plate from placenta at GD 15.5 and 18.5. 15.5/4h: n=6 (control group); n=5 (LPS group); 18.5/4h: n=9 (control group); n=7 (LPS group). CE: Cholesterol Ester; TG: Triacylglycerol; FFA: Free Fatty Acids; CHO: Free Cholesterol; MG: Monoacylglycerol; PL: Phospholipids.



Supplementary figure 4: Representative photomicrographies of immunohistochemistry staining of P-gp in higher magnification 4 h after LPS insult at GD15.5 and 18.5 in the labyrinth (Lz) and junctional (Jz) zones of the placenta. n= 5/group. Scale bar =50 μ m. Normal serum was incubated with negative control sections instead of the P-gp primary antibody.



Supplementary figure 5: Representative photomicrographies of immunohistochemistry staining of Bcrp in higher magnification 4 h after LPS insult at GD15.5 and 18.5 in the labyrinth (Lz) and junctional (Jz) zones of the placenta. n= 5/group. Scale bar =50 μ m. Normal serum was incubated with negative control sections instead of the Bcrp primary antibody.



Supplementary figure 6: Representative photomicrographies of immunohistochemistry staining of Abcg1 in higher magnification 4 h after LPS insult at GD15.5 and 18.5 in the labyrinth (Lz) and junctional (Jz) zones of the placenta. n= 5/group. Scale bar =50 μ m. Normal serum was incubated with negative control sections instead of the Abcb1 primary antibody.